Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year?

Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie Halland; Emma Vernon; Petra Ambs; Roy Fleischmann

首页> 外文期刊>Arthritis & Rheumatism >Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year?

【24h】

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year?

机译：在对甲氨蝶呤反应不足的类风湿性关节炎患者中，Tocilizumab抑制结构性关节损伤：tocilizumab安全性随机对照试验的双盲治疗阶段的结果，并在一年内预防了结构性关节损伤？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Novartis Pharma, Basel, Switzerland

机译：瑞士巴塞尔的诺华制药

著录项

来源
《Arthritis & Rheumatism》 |2011年第3期|609-621|共13页
作者
Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie Halland; Emma Vernon; Petra Ambs; Roy Fleischmann;
展开▼
作者单位

Albany Medical College and the Center for Rheumatology Albany New York;

Hospital Marqués de Valdecilla Santander Spain;

Rheumatology and Internal Diseases Clinic and Pomeranian Medical University Szczecin Poland;

Hospital General de México and Universidad Nacional Autónoma de México Mexico City Mexico;

Panorama Medical Center Cape Town South Africa;

Roche Welwyn UK;

Roche Basel Switzerland;

Metroplex Clinic Research Center Dallas Texas;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
专利

1. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. [J] . Kremer JM, Blanco R, Brzosko M, Arthritis and Rheumatism . 2011,第3期

机译：在甲氨蝶呤反应不充分的类风湿关节炎患者中，Tocilizumab抑制结构性关节损伤：tocilizumab安全性随机对照试验的双盲治疗阶段的结果，并在一年内预防了结构性关节损伤。
2. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results [J] . FleischmannR.M., HallandA.-M., BrzoskoM., The Journal of rheumatology . 2013,第2期

机译：Tocilizumab抑制类风湿关节炎患者的结构性关节损伤并改善其身体功能，并且对甲氨蝶呤的反应不足：LITHE研究的2年结果
3. Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone† [J] . Patrick Garnero, Elizabeth Thompson, Thasia Woodworth, Arthritis & Rheumatism . 2010,第1期

机译：类风湿关节炎对甲氨蝶呤反应不佳的抗白细胞介素6受体抑制剂托珠单抗加甲氨蝶呤对骨骼和软骨转换指标的快速和持续改善：多西环素双盲，安慰剂对照多中心研究的亚组研究结果甲氨蝶呤反应不足的患者中†
4. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised double-blind placebo-controlled phase 3 trial [O] . Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, -1

机译：抗RANKL抗体denosumab对类风湿关节炎患者使用传统的合成疾病缓解性抗风湿药治疗的关节结构损伤的影响（DESIRABLE研究）：一项随机双盲安慰剂对照的3期试验
5. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu [O] . Joel M. Kremer, Ricardo Blanco, Marek Brzosko, 2011

机译：对甲磺酸抑制了类风湿性关节炎患者的结构性关节损伤，对甲氨蝶呤的反应不足：随机安慰剂对照试验的双盲治疗阶段对檀香安全性和预防结构的结果

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year?

摘要

著录项

相似文献

相关主题

期刊订阅